{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/ankylosing-spondylitis/background-information/complications/","result":{"pageContext":{"chapter":{"id":"ff462ad5-64de-5366-801e-9806962bcf65","slug":"complications","fullItemName":"Complications","depth":2,"htmlHeader":"<!-- begin field 60d360d2-67e1-41fb-8ff9-0a50d5032967 --><h2>What are the complications?</h2><!-- end field 60d360d2-67e1-41fb-8ff9-0a50d5032967 -->","summary":"","htmlStringContent":"<!-- begin item dc16ee52-6d6f-41f3-bd0c-74faa70d02f8 --><!-- begin field b52fb513-8561-4f3d-b35b-73a84ae08438 --><ul><li><strong>Complications of axial spondyloarthritis include:</strong><ul><li><strong>Ankylosis or spinal fusion</strong> resulting from new bone formation [<a class=\"bibliography-reference internal-reference\" href=\"/topics/ankylosing-spondylitis/references/\">Millner et al, 2016</a>].</li><li><strong>Spinal fractures: </strong><ul><li>People with spinal rigidity from the formation of syndesmophytes and osteoporosis have a fracture rate of up to 10%, which in some cases is associated with spinal cord injury [<a class=\"bibliography-reference internal-reference\" href=\"/topics/ankylosing-spondylitis/references/\">Taurog et al, 2016</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/ankylosing-spondylitis/references/\">NICE, 2017b</a>].</li></ul></li><li><strong>Hip involvement</strong>, affecting about a third of people with ankylosing spondylitis, which may require joint replacement [<a class=\"bibliography-reference internal-reference\" href=\"/topics/ankylosing-spondylitis/references/\">BMJ Best Practice, 2018</a>].</li><li><strong>Anterior uveitis (iritis)</strong> — lifetime prevalence of 30–40% in people with ankylosing spondylitis, particularly in males and people who are positive for HLA-B27 [<a class=\"bibliography-reference internal-reference\" href=\"/topics/ankylosing-spondylitis/references/\">Taurog et al, 2016</a>].  </li><li><strong>Osteoporosis</strong> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/ankylosing-spondylitis/references/\">McAllister et al, 2017</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/ankylosing-spondylitis/references/\">NICE, 2017a</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/ankylosing-spondylitis/references/\">NICE, 2017b</a>]. Occurs in up to a third of people with anklyosing spondylitis [<a class=\"bibliography-reference internal-reference\" href=\"/topics/ankylosing-spondylitis/references/\">BMJ Best Practice, 2018</a>].    </li><li><strong>Cardiac complications:</strong><ul><li>The risk of cardiovascular disease is thought to be increased in people with spondyloarthritis, due to the systemic inflammatory nature of the condition. Long-term use of NSAIDs may also contribute to this risk, although it is unclear in this specific population [<a class=\"bibliography-reference internal-reference\" href=\"/topics/ankylosing-spondylitis/references/\">Taurog et al, 2016</a>]. It is therefore particularly important to identify and manage modifiable cardiovascular risk factors [<a class=\"bibliography-reference internal-reference\" href=\"/topics/ankylosing-spondylitis/references/\">Peters et al, 2004</a>].</li><li>Cardiac complications of ankylosing spondylitis also include aortic and non-aortic valvular heart disease and congestive heart failure. Arrhythmias may also be present (for example ventricular and supraventricular extrasystoles) [<a class=\"bibliography-reference internal-reference\" href=\"/topics/ankylosing-spondylitis/references/\">NICE, 2017b</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/ankylosing-spondylitis/references/\">BMJ Best Practice, 2018</a>].</li></ul></li><li><strong>Lung involvement</strong> such as restrictive pulmonary disease and apical fibrosis. Dyspnoea may occur as a result of costovertebral involvement decreasing vital capacity [<a class=\"bibliography-reference internal-reference\" href=\"/topics/ankylosing-spondylitis/references/\">NICE, 2017b</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/ankylosing-spondylitis/references/\">BMJ Best Practice, 2018</a>]. </li><li><strong>Neurological involvement</strong> from vertebral fracture, dislocation, or cauda equina syndrome (sensory disturbance in lower limbs and perineum) [<a class=\"bibliography-reference internal-reference\" href=\"/topics/ankylosing-spondylitis/references/\">NICE, 2017b</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/ankylosing-spondylitis/references/\">BMJ Best Practice, 2018</a>]. </li><li><strong>Adverse effects from drugs</strong> used to treat the condition, for example NSAIDs (gastritis, ulcers, renal effects), biological DMARDs (infection, immunosuppression, malignancy) [<a class=\"bibliography-reference internal-reference\" href=\"/topics/ankylosing-spondylitis/references/\">McAllister et al, 2017</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/ankylosing-spondylitis/references/\">NICE, 2017b</a>]. </li><li><strong>Decreased quality of life and work productivity</strong> due to pain, stiffness, fatigue, reduction in spinal mobility and physical function, and sleep problems [<a class=\"bibliography-reference internal-reference\" href=\"/topics/ankylosing-spondylitis/references/\">Dean et al, 2014</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/ankylosing-spondylitis/references/\">Kiltz et al, 2017</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/ankylosing-spondylitis/references/\">Bohn et al, 2018</a>].  <ul><li>A UK cohort study of 570 people calculated a cost of £19,016 per person with ankylosing spondylitis per year. Most of the cost was attributed to lost working hours, early retirement, and unpaid carers time. In the study, 43% of people of working age were not working (because of ankylosing spondylitis in more than 70%); mean age of retirement was 53.6 years; and 3.5% of work time was missed [<a class=\"bibliography-reference internal-reference\" href=\"/topics/ankylosing-spondylitis/references/\">Cooksey et al, 2015</a>].</li></ul></li></ul></li></ul><!-- end field b52fb513-8561-4f3d-b35b-73a84ae08438 --><!-- end item dc16ee52-6d6f-41f3-bd0c-74faa70d02f8 -->","topic":{"id":"228aa309-0970-5ae0-a937-1a670214e066","topicId":"0752afda-bf5b-48c4-b4af-e842f0a9b229","topicName":"Ankylosing spondylitis","slug":"ankylosing-spondylitis","lastRevised":"Last revised in May 2019","chapters":[{"id":"1318829b-e445-59f5-8079-ced63414cf7e","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"28658e82-53d5-5798-84bf-7e67cc233b06","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"bc7876cf-e413-557d-b763-1b8198ae3cb7","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"b83be00a-c774-50aa-b8be-a04912f19bd5","slug":"changes","fullItemName":"Changes"},{"id":"ecb29915-59e9-5752-9bbb-fc44515688b3","slug":"update","fullItemName":"Update"}]},{"id":"81161324-4d7b-5419-85a9-dae9f57fa83b","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"c127b8df-f565-5637-adb8-bafbfd767c40","slug":"goals","fullItemName":"Goals"},{"id":"091c0d27-63a5-548e-8f08-5bfb48e416a7","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"f9ca120c-2183-5429-9706-101fc20540e1","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"58752ac1-77db-5b74-8e2e-bf0081dd74fd","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"ffa55c0b-7b3d-583c-8a67-f0372230cbf9","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"4c33c07f-65b3-572b-b4c0-1eecffd16191","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"f4a7a8d2-8847-5779-9892-e4867ecaacdd","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"8c9e7d3f-07eb-5b06-9f42-67f6c18e4ce2","slug":"definition","fullItemName":"Definition"},{"id":"64b026f5-a69f-5ef8-800d-7aee9ac65509","slug":"causes","fullItemName":"Causes"},{"id":"fc3d12c0-7b54-576d-ba75-e8570df23bf0","slug":"prevalence","fullItemName":"Prevalence"},{"id":"ff462ad5-64de-5366-801e-9806962bcf65","slug":"complications","fullItemName":"Complications"},{"id":"76129f0b-5489-511d-bc1d-565b990f4fb8","slug":"prognosis","fullItemName":"Prognosis"}]},{"id":"a54d37d1-407b-50c4-b5e8-c98891ee1e00","fullItemName":"Diagnosis","slug":"diagnosis","subChapters":[{"id":"6a2b7eca-b47b-5a11-9909-91a6aea6835a","slug":"diagnosis","fullItemName":"Diagnosis"},{"id":"ea0d0799-6976-5240-92c5-4623f9074fda","slug":"investigations","fullItemName":"Investigations"},{"id":"58c6e66c-a8a5-56c9-8c47-7127807d9c73","slug":"differential-diagnosis","fullItemName":"Differential diagnosis"}]},{"id":"5f2d8235-d927-54d7-bd0a-4ec15e3336b8","fullItemName":"Management","slug":"management","subChapters":[{"id":"0a3569b1-7ede-51ad-abdd-77173b02733e","slug":"suspected-ankylosing-spondylitis","fullItemName":"Scenario: Suspected ankylosing spondylitis"},{"id":"3e6db8e8-b2dc-5a7a-9fe2-0a341c7c963d","slug":"confirmed-ankylosing-spondylitis","fullItemName":"Scenario: Confirmed ankylosing spondylitis"}]},{"id":"b82cc559-18dd-500a-add0-dde6d8b59e63","fullItemName":"Prescribing information","slug":"prescribing-information","subChapters":[{"id":"76b292a6-865e-5dcd-9885-3e235e7664a4","slug":"oral-nsaids","fullItemName":"Oral NSAIDs"},{"id":"113dcc0f-4841-54a0-9101-a64009316e7c","slug":"proton-pump-inhibitors-ppis","fullItemName":"Proton pump inhibitors (PPIs)"},{"id":"52667269-49b0-5132-839c-67d58b9480db","slug":"paracetamol-codeine","fullItemName":"Paracetamol and codeine"}]},{"id":"59c2b871-f61e-5fb4-a894-cae5bdeda4bd","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"80288a50-5bef-5779-8bf9-7d8abf169080","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"932977c5-3d44-5c3b-8787-7de309af3820","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"eb5fa8b8-2845-567c-ab0a-2274329dfc51","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"c4153414-1fd0-5779-a348-78ee4ab85730","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"12b49dd2-6a18-5e19-8960-15901b6a91b7","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"83d1e8ec-8cac-5c4a-ac1b-758b9b2501bb","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"67d800ae-fb2a-559a-89de-a4813d740021","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"f4a7a8d2-8847-5779-9892-e4867ecaacdd","slug":"background-information","fullItemName":"Background information"},"subChapters":[]}}},"staticQueryHashes":["3666801979"]}